Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  gefitinib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 160 for your search:
Start Over
PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC)
Phase: Phase IV
Type: Natural history/Epidemiology, Treatment
Status: Closed
Age: 20 and over
Sponsor: Other
Protocol IDs: 9461700718, NCT00173524
Iressa Case Control Study in Japan
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Completed
Age: No age specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: D791AL00002, V-15-33, OZV1533, NCT00252759
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 19 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: D7913L00067, NCT00608868
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D7913L00071, NCT00770588
A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Status: Completed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1839IL/0052 SubStudy, NCT01000740
An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1839IL/0052, D7914C00052, NCT00684385
Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D791AC00014, NCT01203917
A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to5
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1839IL/0143, NCT00234429
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TLK286.3020, NCT00080340
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI UNKPRI 12, NCT00193596
Iressa 2nd Line Phase III Study in Japan
Phase: Phase III
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D791AL00001, V-15-32, NCT00252707
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D791AC00007, Iressa Pan Asian Study (IPASS), NCT00322452
Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000492254, NCCTG-N05C4, N05C4, NCT00362986
Iressa Follow-up Trial
Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1839IL/0555, D7913L00008, NCT00357734
First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: NCCCTS-05-126, D7913L00054, NCT00455936
Randomized Gefitinib Trial
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: ONC-2008-001, NCT00807066
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1839IL/0704, EudraCT no.2004-002662-38, NCT00206219
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: NCI-2012-03041, S0023, U10CA032102, CDR0000068706, SWOG-S0023, CAN-NCIC-BR15, NCCTG-S0023, BR15, NCT00020709
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00650, SWOG-CAN-NCIC-BR19, ECOG-CAN-NCIC-BR19, BR19, CDR0000258118, CAN-NCIC-BR19, NCIC-BR.19, NCT00049543
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 13021, H3E-CR-S131, NCT01017874
Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000689080, OXFORD-COG, UO-COG, EUDRACT-2007-005391-13, ISRCTN-29580179, AZ-D7913L00059, EU-21085, COG, NCT01243398
Start Over